CASE REPORT

1. Daniel Alcides Carrión National Hospital, Callao, Peru
   a. Obstetrician/gynecologist, Daniel Alcides Carrión National Hospital, Callao, Peru; Center for Fetal Medicine - CENMEF, Maternal-Fetal Medicine Group – Fetalis
   b. Pathologist, Daniel Alcides Carrión National Hospital, Callao, Peru; Arias Stella Pathology and Molecular Biology Institute
   c. Resident physician in OB/GYN

Funding: The authors received no specific funding for this study.

Conflict of interest: The authors have no conflict of interest.

Received: 2 February 2020
Accepted: 4 February 2020
Online publication: 8 June 2020

Correspondence:
Dr. Rommel Lacunza Paredes
drlacunza@hotmail.com


ABSTRACT
Placental massive perivillous fibrinoid deposition or maternal floor infarction is a rare entity associated with intrauterine growth restriction, fetal death and poor perinatal outcome. It is characterized by the perivillous deposition of fibrinoid material, without a clear etiology. We present the first documented case in Peru.

Key words: Placenta, perivillous fibrin deposition, Fetal growth restriction.

RESUMEN
El depósito fibrinoide perivelloso masivo o infarto del piso materno de la placenta es una entidad rara, que presenta relación con restricción del crecimiento fetal, óbito fetal y mal resultado perinatal. Se caracteriza por el depósito perivellositario de material fibrinoide sin etiología clara. Se presenta el primer caso documentado en el Perú.

Palabras clave. Placenta, depósito perivelloso de fibrina, Restricción del crecimiento intrauterino.

INTRODUCTION

Massive perivillous fibrinoid deposition or maternal floor infarction is a rare condition occurring in 0.3 to 0.5% of all pregnancies(1). The exact pathophysiological mechanism of this “fibrinoid” deposition around chorionic villi is unknown, but diverse etiologies have been proposed: infections, autoimmune diseases (lupus), antiphospholipid syndrome, maternal coagulopathy, angiogenic-antiangiogenic disequilibrium and chronic intervillositis(2-3). Most series are retrospective and study the placenta in relation to intrauterine growth restriction, fetal death and poor perinatal outcome. We present the first case report in our country of severe intrauterine growth restriction with sonographic placental abnormalities and the definitive pathology diagnosis of massive perivillous fibrinoid deposition.

CASE REPORT

A primiparous patient, 36 weeks and 2 days pregnant by early ultrasound, was evaluated in the emergency room for decreased fetal movements. Her fundal height was 27 cm.

The following measurements were obtained on the ultrasound scan: biparietal diameter (BPD) 84 mm (4th percentile), head circumference (CC) 308 mm (p<3), abdominal girth (AG) 281 mm (p<3), femur length (FL) 59 mm (p<3), average fetal weight 1 921 g ±284 g, below the 3rd percentile for gestational age (GA); the ultrasound also revealed oligohydramnios. Further findings were anterior placenta located in the uterine body, heterogeneous and thick (67 mm), with multiple hyperechoic areas either in
the basal plate or throughout its thickness, and hypoechoic areas in the center of the cotyledon, suggesting perivillous thrombosis (Figure 1). On the Doppler ultrasound, the umbilical arterial pulsatility index (PI) was 1.26 (appropriate for GA [AGA]), the middle cerebral artery pulsatility index was 0.92 (altered, below the 5th percentile for GA) and the peak systolic velocity was 72 cm/s (greater than 2.5 multiples of the median [MoM] for GA), venous duct PI was 0.61 and the average PI of the uterine arteries was 0.8 (AGA). The patient was diagnosed with late fetal growth restriction, with signs of flow redistribution and placentomegaly.

A female newborn was delivered through an emergency C-section, weighing 2155 g, with a height of 44 cm and an Apgar score of 8 and 9 at minutes 1 and 5, respectively. At macroscopic examination, most placental cotyledons were yellowish grey in the maternal surface and yellowish in the fetal surface. Serial sectioning revealed the maternal surface was whitish yellow, with variable thickness, expanding to the fetal surface in some areas, forming irregular tracts. Some cotyledons had perivillous thrombi (Figures 2 and 3). Upon macroscopy and microscopy, a diffuse deposition of fibrinoid material was noted in more than 50% of the villi, extending from the maternal into the fetal surface. Some areas also had perivillous thrombi (figure 4). The newborn progressed favorably, without requiring advanced life support, and was discharged from the neonatology service 7 days later.

Discussion

The concept of maternal floor infarction (MFI) was proposed by Benirschke and Driscoll[4] to describe the deposition of fibrinoid material—it is not really a vascular occlusive phenomenon. Afterwards, Fox[5] defined massive perivillous fibrinoid deposition (MPFD) as a fibrin deposition compromising most of the placenta; this deposition can be transmural. Both terms have been used in a similar way in the literature, as part of the spectrum of a single disease. Katzman[6] proposed a semiquantitative classification: maternal floor infarction (fibrinoid material in the maternal surface, over 3 mm thick), transmural or severe MPFD (fibrinoid material extends from the maternal into the fetal surface, compromising over 50% of the villi in one slide), borderline or moderate MPFD (fibrinoid material extends transmurally or quasi-transmurally, compromising 25 to 50% of the villi in one slide), and non-classifiable disease.

Diagnosis is obtained through histology. At macroscopy, the placental maternal surface is whitish, grayish or yellowish. Serial sections of the placenta show irregular and sinuous white yel-

Figure 1 A-B. Ultrasound image of heterogeneous placenta. The yellow arrows point at hyperechoic areas in the maternal surface, corresponding to areas of massive perivillous fibrinoid deposition. White arrow: central hypoechoic area in the cotyledon, suspicious for intervillous thrombus.
Placental massive perivillous fibrinoid deposition causing severe intrauterine growth restriction

These characteristics were clearly observed in the case we report (Figures 2 and 3). Microscopic examination reveals the perivillous deposition of a “fibrinoid” substance closing the space without collapsing it, surrounding viable and atrophic chorionic villi. This fibrinoid substance consists of a mixture of blood proteins such as fibrin, basal membrane collagen, fibrinogen, fibronectin and laminin. Figure 4 shows the slide that established the definitive histopathological diagnosis in our case. This condition is frequently associated with perivillous thrombosis, ischemic villitis, plasma cell deciduitis and villitis of uncertain significance (2,3,6,7).
The placental ultrasound may show heterogeneous hyperechoic areas in the maternal surface that might extend to the fetal surface, usually with increased placental thickness\(^8\),\(^9\). These hyperechoic areas are showed in Figure 1. Frequently, these findings present with other images suggestive of perivillous thrombosis and placental infarction\(^8\),\(^9\). Figure 3 links ultrasound findings to placental macroscopy, showing that heterogeneous hyperechoic areas correspond with perivillous fibrinoid deposition.

The most frequent clinical presentation is intrauterine growth restriction (IUGR), with an incidence between 31 and 100%. It may be of early or late onset and, on some occasions, present with alterations in the fetal or maternal Doppler ultrasound. Table 1 summarizes the main series that relate MPFD to IUGR. Devisme\(^{11}\) found 71 cases of MPFD among 6971 placentas, which he classified as severe (50% of the villi were compromised in one slide) or moderate (25 to 50% of the villi were compromised). The incidence of IUGR was

![Figure 4 A. Full slide image showing perivillous fibrin extending from the maternal into the fetal surface, compromising ≥50% of villi in ≥ 1 slide. B. Enlargement of A, where chorionic villi (black arrows) are surrounded by abundant fibrinoid material. C. Image of a perivillous thrombus surrounded by chorionic villi with fibrin.](image-url)
93 and 82% in each group respectively, with Doppler alterations of the uterine arteries in half of the cases. 60% of the cases with Doppler alterations of the uterine artery had severe MPFD, and 25% had moderate MPFD. Spinillo[16], in a prospective series of 355 fetuses with IUGR, obtained a global MPFD incidence of 11.8% (incidence of 3.1% for severe and of 8.7% for moderate cases). Deterioration in fetal Doppler ultrasound findings was more frequent in severe cases, mainly due to an alteration of the pulsatility index (36% vs 22%); this deterioration did not evidence absent nor reversed end-diastolic flow. Vasodilation of the middle cerebral artery was more frequent in severe cases (54% vs 25%). These results show that placental insufficiency would not be the only explanation for an adverse perinatal outcome; the concomitance of placental vascular alterations and inflammation could also explain this phenomenon. Studying the placentas of 54 cases compatible with MPFD and IUGR, Spinillo[14] found that they were at a higher risk for alterations of the umbilical artery in the Doppler ultrasound (OR 1.2, PI over the 95th percentile, 2.1 for absent or reversed diastole), without further Doppler compromise in relation to the severity of MPFD. In the Doppler assessment of the MCA of the case we report, we found vasodilation and an altered cerebroplacental index, evidencing flow redistribution in relation to placental insufficiency. It is worth noting that the increase in the peak systolic velocity of the MCA still has no clear explanation.

Another frequent clinical presentation is fetal death, with a reported incidence of 17 to 50%[7,11,15] (see Table 1). In a study of 575 placentas from cases of fetal death, Man[18] identified placental pathologies in 19%, of which 10% were MPFD, most of which belonged to third trimester fetal deaths. Similarly, Devisme[11] reports an incidence of fetal deaths of 9% in cases of severe MPFD and of 2% in cases with moderate disease.

A very important issue in the management of MPFD is the risk of recurrence in the following pregnancies, which may be up to 30%[2,13]. Because of this, studying the placenta of a fetus with IUGR is critical for future pregnancies. Some case reports mention treatments, such as aspirin or low-molecular-weight heparin, that were used in specific patients who had no recurrent disease in subsequent pregnancies, and gave birth to children with good perinatal outcomes[13,17].

**References**

15. Mandsager NT, Bendon R, Mostello D, Rosenn B, Mio-
